Detalhe da pesquisa
1.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Br J Haematol
; 185(3): 450-467, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729512
2.
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Biol Blood Marrow Transplant
; 22(6): 1009-1016, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827659
3.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(8): 874-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948586
4.
Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL.
Leuk Res Rep
; 9: 5-8, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29264111
5.
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Lancet Haematol
; 3(7): e340-51, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27374467